Key Drivers
- High gross margin
- Strong free cashflow
- Quarterly margin drop
AIAI Summary
Edwards' thesis has shifted from a single‑product TAVR cash machine to a multi‑franchise structural‑heart platform—reducing product concentration risk but making near‑term earnings highly dependent on successful execution across several discrete launches and reimbursement wins. Monitor SAPIEN M3 U.S. rollout (commercial training, CMS coverage timing) plus quarterly margin trajectory and capital allocation (buybacks vs. R&D) as the specific catalysts that will re‑rate or punish the stock.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High gross margin
- •Strong free cashflow
- •Quarterly margin drop
EW combines very high margins, strong FCF and low leverage but a pronounced quarterly profit decline, large intangibles and rich valuation that increase downside risk.
Price Behavior
Key Price Behavior Insights:
- •Below last-month SMA
- •Tight range
- •Mid‑80s cap
Price is mildly below its last-month average (~$83.8) with RSI ~41, trading in a tight range above the Feb low near $79.78 and capped by mid‑80s resistance (~$85.7–87.2), implying short-term weakness but possible rebound at support.
Price ~1.6% below last-month
Sentiment & News
Key News Insights:
- •TMTT acceleration
- •2026 sales guide
- •Mixed institutional flows
Edwards Lifesciences posts durable product-driven growth, strong TMTT momentum and upbeat 2026 guidance, drawing moderate buy analyst sentiment and mixed but active institutional flows.
Continued product adoption and strong TMTT growth should support share-performance upside while near-term investor attention remains elevated
Similar Companies in Healthcare
Other companies in the same sector with AI ratings